Publication: Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: A qualitative study and the development of a patient-centered conceptual model
This research article, published in the Journal of Patient Reported Outcomes, describes the development of a conceptual model of the symptoms and impacts of nonsense mutation Duchenne muscular dystrophy (nmDMD), based on qualitative interviews with caregivers
Review the process used to undertake a qualitative study involving interviews with 10 caregivers of patients with nmDMD in the UK
Discover the symptoms and impact of nmDMD before and after treatment with a mutation-specific therapy, as reported by caregivers
Learn about a conceptual model, illustrating the relationships between symptoms and impacts of nmDMD before treatment
Williams K, Davidson I, Rance M, et al. J Pat-Rep Outcomes. 2021;5:75
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200033 | March 2022
Sign in or register to access exclusive content on this site